Themis Medicare Limited · NSE:THEMISMED
Themis Medicare — Q1 FY26 Earnings Presentation
19 slides from Themis Medicare's earnings presentation, Aug 1, 2025
Slide 1: Exchange filing cover letter: Investor Presentation
TML/BSE/NSE/2025-26/17 1st August, 2025 The Manager The Manager – Listing Department Corporate Relationship Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Dalal Street, Mumbai- 400001 Bandra (East), Mumbai- 400051 Scrip
Slide 2: Themis Medicare Ltd. Result Update Presentation Q1 FY26
In every possibility lies an innate, latent power to change lives Themis Medicare Ltd. Result Update Presentation Q1 FY26
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Themis Medicare Limited (the “Company” or “Themis” or “TML”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in
Slide 4: Table of Contents
Table of Contents Consolidated Financial Highlights Company Overview Way Ahead 3
Slide 5: Management Comment
Management Comment Commenting on the result, Dr. Sachin Patel, Managing Director & CEO, said: “The Company’s performance in this quarter was significantly impacted due to disruption in a high margin major line of Business on account of substandard imitation in the market. In this regard, the Company
Slide 6: Consolidated Financial Highlights
Consolidated Financial Highlights
Slide 7: Consolidated Quarterly Financial Highlights
Consolidated Quarterly Financial Highlights Revenue (Rs. Cr.)* EBITDA (Rs. Cr.)** / Margin (%) 123.0 117.0 97.6 23.7% 93.8 71.7 14.6% 9.1% 29.2 17.1 -8.1% 8.5 -10.3% Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 -5.8 -10.1 PAT (Rs. Cr.) / Margin (%) EPS (Rs.) 20.1%
Slide 8: Consolidated Quarterly Financial Highlights – Q1 FY26
Consolidated Quarterly Financial Highlights – Q1 FY26 Particulars (Rs. Cr.) Q1 FY26 Q1 FY25 Y-o-Y (%) Q4 FY25 Net Revenue 97.58 122.99 71.70 Cost of Material Consumed 12.43 23.52 18.98 Purchase of SIT 21.68 16.74 16.30 Changes in Inventory 18.29 1.01 (14.68) • Formulation Segment grew Employee Expen
Slide 9: Consolidated Financial Highlights – FY25
Consolidated Financial Highlights – FY25 Particulars (Rs. Cr.) FY25 FY24 Y-o-Y (%) Net Revenue 405.51 381.76 6.22% Cost of Material Consumed 76.31 84.67 Purchase of SIT 73.67 53.61 Changes in Inventory (17.98) (1.57) Employee Expenses 96.38 82.41 Other Expenses 128.10 111.13 Total Expenditure 356.46
Slide 10: Consolidated Balance Sheet as on 31st Mar'25
Consolidated Balance Sheet as on 31st Mar’25 As on 31st As on 31st As on 31st As on 31st Rs. Cr. Rs. Cr. Mar’25 Mar’24 Mar’25 Mar’24 Shareholders Funds 402.60 377.67 Non Current Assets 284.17 273.25 Share Capital 9.20 9.20 Plant, Property & Equipment 172.03 167.81 Other Equity 393.39 368.46 Capital
Slide 11: Company Overview
Company Overview
Slide 12: Snapshot of Company
Snapshot of Company Strategic focus To become Leader in Hospital Business in India with 4 Strong Balance Sheet growing divisions contributing 38.25% to revenue in Total Debt to Equity at 0.21 FY24-25 in FY24-25 3 State of art manufacturing facilities in India – Rs. 1,197 Cr 1 Formulations and 2 APIs
Slide 13: Strong Business Model
Strong Business Model 01 Businesswise Revenue – Q1 FY26 Hospital Business API, Co. Mkt & Others is major growth 03 29% Hospital driver 45% Trade 26% n 02 Hospital Business n API Business ▪ Critical Care Division ▪ API Legacy Business ▪ Intensive Care Division ▪ New Product pipeline Businesswise Reve
Slide 14: Vertically Integrated State of Art Manufacturing Capabilities
Vertically Integrated State of Art Manufacturing Capabilities Location Particulars Haridwar Hyderabad Vapi Artemis Biotech Themis Medicare Ltd. Themis Medicare Ltd. (Division of Themis Medicare Ltd.) Segment Formulations Synthetic APIs Synthetic APIs Tablets (Nos.) - 520 mn Ointment (No. of Tubes) -
Slide 15: Strong Research and Development Capabilities
Strong Research and Development Capabilities Continued Investment in R&D (Rs. Cr.) Business API Formulations 14.25 13.64 13.69 13.21 R&D 15 4 Analytical Lab 8.50 7 5 Development Product in a year with 5–8 20-24 documentation FY20-21 FY21-22 FY22-23 FY23-24 FY24-25 Products in work rolling 3–5 31 14
Slide 16: Way Ahead
Way Ahead
Slide 17: Hospital Business Opportunity
n Hospital Business Opportunity Why Hospital Business Segment? ▪ Growing market - Themis has strong foot in door through Critical Care ▪ Market Highly Fragmented unlike West where 3-4 players control 90% market share ▪ Opportunities to grow segments within HB High Entry Barriers ▪ Large Product Port
Slide 18: Our Aspirations
Our Aspirations Vision & Position ▪ Provide hospitals and health systems ‘The Best Experience Leader business model” to ensure customer satisfaction ▪ Leadership in Anesthesia and Critical Care Strategy ▪ Focus on Hospital business ▪ APIs to be developed - in-house New Target Markets consumption and
Slide 19: Thank You
Thank You It takes one word to change the world “POSSIBILITY” For further information, please contact: Mr. Pradeep Chandan Mr. Amit Sharma / Mr. Rahul Trivedi Tel: +91 9867726686 / 9833541841 Themis Medicare Ltd Email: pradeep.chandan@themismedicare.com Adfactors PR Pvt Ltd Website: www.themismedica